Aetna will reimburse for the use of EXPAREL in ambulatory surgical centers in Florida and New Jersey as part of a pilot program
PARSIPPANY, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aetna has announced that they will reimburse select ambulatory surgical centers (ASCs) for the use of EXPAREL® (bupivacaine liposome injectable suspension) as part of a pilot program in Florida and New Jersey. The purpose of the program is to incentivize the use of non-opioid therapies for postsurgical pain management in ASCs.
This expanded coverage of EXPAREL advances Aetna’s clinical strategy of supporting increased member access to non-opioid pain treatment options and encouraging reductions in inappropriate opioid prescribing. In 2017, the company began reimbursing for EXPAREL for select impacted third molar (wisdom tooth) extractions. EXPAREL provides patients prolonged pain control that can help reduce or eliminate reliance on opioids, their associated side effects and the long-term risks of addiction or dependence.
“Aetna is demonstrating its commitment to addressing the opioid epidemic by leading the way in expanding coverage of EXPAREL in the ASC setting,” said Dave Stack, chairman and chief executive officer at Pacira Pharmaceuticals. “We look forward to continuing our work with Aetna to prevent future opioid misuse or dependence by providing a safer, non-opioid option like EXPAREL for all patients undergoing surgery.”
Studies continue to show that surgery is an inadvertent gateway to persistent opioid use. According to new research examining seven orthopedic and soft tissue surgical procedures, patients were prescribed an average of 82 opioid pills to manage postsurgical pain. Approximately 9 percent of surgical patients became newly persistent users in 2017, continuing to take these opioids at least three to six months after their operation1. Unused opioids after surgery also pose the risk of diversion, another avenue to opioid misuse or dependence.
The reimbursement for EXPAREL in the ASC setting is demonstrative of Aetna’s ongoing collaborations with Pacira to combat the opioid epidemic. Recent initiatives include Aetna’s update to its online provider directory to help members easily identify surgeons who are trained to administer EXPAREL, as well as the creation of a national program launched by Pacira, Aetna and the American Association of Oral and Maxillofacial Surgeons (AAOMS). The program aims to reduce the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Aetna is one of the nation’s leading diversified health care benefits companies, serving an estimated 38.8 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers’ compensation administrative services and health information technology products and services. Aetna’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com and learn about how Aetna is helping to build a healthier world. @AetnaNews
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks, or intravascular or intra-articular use. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL. Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesias. CNS reactions are characterized by excitation and/or depression. Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias sometimes leading to death. Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients. Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.
Pacira Pharmaceuticals, Inc.
Amber Sears, (973) 254-3587
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
1 Pacira. Exposing a Silent Gateway to Persistent Opioid Use – A Choices Matter Status Report. October 2018. [Analysis in the report was based on research conducted by IQVIA and Wakefield Research].
Pacira Pharmaceuticals, Inc.